Idenix Pharmaceuticals Newswire

Idenix Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Idenix Pharmaceuticals.

Results 1 - 18 of 18 in Idenix Pharmaceuticals

  1. What You Need to Know About Tango TherapeuticsRead the original story w/Photo

    Monday Jan 15 | BioSpace

    ... of Tango and for Neon Therapeutics. Prior to those positions, she was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. Alexis Borisy - chairman . Borisy is a partner at Third Rock Ventures, which he ...

    Comment?

  2. Dow 30 Earnings: Merck and Co. Third Quarter 2017Read the original story

    Oct 27, 2017 | Value Line

    ... (arthritis). In 2014, the company made three significant acquisitions: Schering-Plough (January), Idenix Pharmaceuticals (June), and Cubist Pharmaceuticals (December). At the time of this article's writing, the author did not have positions in any ...

    Comment?

  3. Belgian scientists claim Delaware wrongly seized, sold stockRead the original story

    Oct 13, 2017 | The Gazette

    ... Jean Louis Imbach argued that Delaware had no legal authority to seize their foreign-owned shares in Idenix Pharmaceuticals Inc. The company was incorporated in Delaware in 2002 as the successor to a firm established in 1998 to develop a new ...

    Comment?

  4. Chief Judge Stark Rejects Motion for Enhanced Damages Award Due to...Read the original story w/Photo

    Oct 12, 2017 | jdsupra.com

    Last month, following a jury verdict in federal district court in Delaware awarding Plaintiff Idenix Pharmaceuticals LLC $2.54 billion in damages - "the largest damages verdict ever returned in a patent [infringement] trial" - Chief Judge Leonard Stark denied Idenix's motion for enhanced damages. Idenix Pharm.

    Comment?

  5. Translate Bio Names Daniella Beckman To Board Of DirectorsRead the original story

    Oct 3, 2017 | BioSpace

    ... including strategic financial planning. Previously, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. At Idenix, she oversaw finance, treasury, capital raises, investor relations and IT. ...

    Comment?

  6. Merck bails on future HCV drugs; shares down 1%Read the original story w/Photo

    Sep 29, 2017 | Seeking Alpha

    ... a $2.9B impairment charge related to R&D for antiviral uprifosbuvir, acquired via its takeout of Idenix Pharmaceuticals in 2014. Johnson & Johnson ( JNJ ) also terminated development of its HCV med, refocusing its efforts on hepatitis B where there ...

    Comment?

  7. Comparing Idenix PharmaceuticalsRead the original story w/Photo

    Sep 26, 2017 | IntersportsWire

    Idenix Pharmaceuticals and Grifols, are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation. This is a summary of recent ratings and target prices for Idenix Pharmaceuticals and Grifols,, as reported by MarketBeat.com.

    Comment?

  8. Grifols, (GRFS) versus Idenix Pharmaceuticals (IDIX) Head-To-Head SurveyRead the original story

    Sep 14, 2017 | The Breeze

    Grifols, and Idenix Pharmaceuticals are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. 21.9% of Grifols, shares are owned by institutional investors.

    Comment?

  9. Comparing Idenix PharmaceuticalsRead the original story w/Photo

    Sep 10, 2017 | IntersportsWire

    Idenix Pharmaceuticals and Grifols, are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability. Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%.

    Comment?

  10. Head-To-Head Analysis: Idenix PharmaceuticalsRead the original story w/Photo

    Sep 6, 2017 | AmericanBankingNews.com

    Idenix Pharmaceuticals and Grifols, are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. 21.9% of Grifols, shares are held by institutional investors.

    Comment?

  11. Lost $12 Million Windfall Sparks Suit Against DelawareRead the original story w/Photo

    Aug 18, 2017 | Wall Street Journal

    The case could have broad implications for state finances around the country and for foreign shareholders of U.S. companies Dr. Gilles Gosselin, above, and Jean Louis Imbach, chemists who developed a drug for treating hepatitis B, became major shareholders of Idenix Pharmaceuticals Inc., which was incorporated in Delaware. In 2009, Delaware took their stock, deeming it abandoned.

    Comment?

  12. Failure to Satisfy Enablement Requirement Results in Priority Award to Junior PartyRead the original story w/Photo

    Aug 3, 2017 | JD Supra

    ... claimed priority to a provisional application filed June 28, 2002. Storer's patent was assigned to Idenix Pharmaceuticals. Another inventor, Clark, filed a patent application on September 12, 2007, with a claim of priority to a provisional ...

    Comment?

  13. Dow 30 Earnings: Merck Second Quarter 2017Read the original story

    Jul 28, 2017 | Value Line

    ... (arthritis). In 2014, the company made three significant acquisitions: Schering-Plough (January), Idenix Pharmaceuticals (June), and Cubist Pharmaceuticals (December). At the time of this article's writing, the author did not have positions in any ...

    Comment?

  14. Viking Therapeutics Appoints To Board Of DirectorsRead the original story

    Jul 5, 2017 | BioSpace

    ... board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. He holds an M.B.A. from Rutgers University and a B.S. from Saint Joseph's University. About Viking Therapeutics, ...

    Comment?

  15. Gilead: How Sweet It IsRead the original story w/Photo

    Jun 23, 2017 | Seeking Alpha

    ... Trial and Appeal Board ruling that Gilead Pharmasset LLC invented a hepatitis C treatment before Idenix Pharmaceuticals LLC and will be granted a patent. The court evaluated Idenix's and Gilead's patent applications on a first-to-invent basis ...

    Comment?

  16. Richard Storer Gilles Gosselin Jean Pierre Sommadossi Paola Lacolla v. Jeremy Clark United StatesRead the original story w/Photo

    Jun 21, 2017 | FindLaw

    ... seeking review of the Board's decision under 35 U.S.C. A 146. The district court dismissed the case, Idenix Pharmaceuticals. LLC v. Gilead Pharmasset LLC, 2016 WL 6804915, at *1 (D. Del. Nov. 16, 2016), based on this court's ruling in Biogen MA, ...

    Comment?

  17. Dow 30 Earnings: Merck First Quarter 2017Read the original story

    May 2, 2017 | Value Line

    ... (arthritis). In 2014, the company made three significant acquisitions: Schering-Plough (January), Idenix Pharmaceuticals (June), and Cubist Pharmaceuticals (December). At the time of this article's writing, the author did not have positions in any ...

    Comment?

  18. This Week In Securities LitigationRead the original story w/Photo

    Mar 24, 2017 | JD Supra

    ... was tipped by a relative who worked at Merck & Co. about his employer's then pending acquisition of Idenix Pharmaceuticals, Inc., announced on June 9, 2014. Mr. Hartung purchased 3,345 shares of Idenix yielding profits of $59,688 following the deal ...

    Comment?